Statistically significant differences were observed in tumor types and treatment regimens: While patients with irNeuropathy had a lower prevalence of hepatocellular carcinoma compared to CCs (p = 0.02; OR, 0.09), they were more likely to have received combination therapy with programmed death (PD)−1 and cytotoxic T-lymphocyte-associated protein (CTLA-)4 inhibitors (p = 0.02; OR, 11.29). The gene discussed is CTLA4; the disease is neoplasm.